Lipocine Inc.LPCN
Price (close)
$2.09
Market cap
$17.2M
P/E
—
Revenue (TTM)
$1.6M
Net income
-$11.9M
Dividend yield
—
1-year total return
-22.0%
Net margin
-755.1%
Revenue growth
-62.7%
Debt / equity
—
What Lipocine Inc. does.
are a biopharmaceutical company focused on leveraging our proprietary technology platform to develop innovative products with effective
oral delivery of previously difficult to deliver molecules. Our proprietary delivery technologies are designed to improve patient compliance
and safety through orally available treatment options. Our primary development programs are based on oral delivery solutions for poorly
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $16.1M | $500,000 | -$2.9M | $11.2M | $2.0M |
| Net income | -$21.0M | -$634,399 | -$10.8M | -$16.4M | $8,352 | -$9.6M |
| Free cash flow | — | -$4.4M | -$12.1M | -$11.9M | -$1.3M | — |
More on LPCN.
- Lipocine Inc. summary
- Lipocine Inc. financial statements
- Lipocine Inc. key metrics
- Lipocine Inc. health scores and style box
- Lipocine Inc. earnings
- Lipocine Inc. dividends
- Lipocine Inc. valuation
- Lipocine Inc. ownership and insiders
- Lipocine Inc. peers
Figures from Lipocine Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.